Floatz logo

Ramifentanyl

Lymphopenia

Guizhi DuSmall moleculeUnknownDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Lymphopenia cohort.

Asset / SponsorPhaseRating
Talfirastide
Tarix Pharmaceuticals
Phase 2CCC
Prag-1
Second Affiliated Hospital of Soochow University
Phase 2CCC
Sevoflurane
Guizhi Du
UnknownD
Propofol
Guizhi Du
UnknownD

Same molecule, other indications

Ramifentanyl is also rated in:

cardiovascular disorderActive
BBB
Indicative · Phase 4
73 / 100
View asset →
morbid obesityActive
BBB
Indicative · Phase 4
73 / 100
View asset →
chronic pain syndromeActive
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →